https://www.pharmaradar360.com/article/17606c0a5a9b4d51PharmaRadar360en2026-04-13T11:48:37.000ZNervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conferencehttps://www.pharmaradar360.com/article/611677eb72f3fcbePharmaRadar360en2026-04-13T11:17:53.000ZEl Informe Anual sobre Cosmetovigilancia registra un aumento del 30% de las notificaciones por efectos no deseados de productos cosméticoshttps://www.pharmaradar360.com/article/1f0b078c77f0622fPharmaRadar360en2026-04-13T11:17:42.000ZDecision: Marketing authorisations granted in 2025https://www.pharmaradar360.com/article/3a1b056abb9791d3PharmaRadar360en2026-04-13T11:00:00.000ZIfinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapyhttps://www.pharmaradar360.com/article/add5af149e28f404PharmaRadar360en2026-04-13T10:45:00.000ZLilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLLhttps://www.pharmaradar360.com/article/b45893a1deb7e1c9PharmaRadar360en2026-04-13T10:00:00.000ZMedtronic to announce financial results for its fourth quarter and full fiscal year 2026https://www.pharmaradar360.com/article/ad6504852721b264PharmaRadar360en2026-04-13T05:00:00.000ZRoche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosishttps://www.pharmaradar360.com/article/0f710c111f870505PharmaRadar360en2026-04-13T05:00:00.000ZThe role of biomarkers: how new modalities are making precision medicine a realityhttps://www.pharmaradar360.com/article/02af197f88ab392bPharmaRadar360en2026-04-13T03:00:00.000Z[IBENTO][IBENTO]The report for the PMDA-ATC Pharmacovigilance Seminar 2026 has been posted.https://www.pharmaradar360.com/article/1f15d45363267479PharmaRadar360en2026-04-13T03:00:00.000Z[SONOTA]Recent Publications by PMDA Staff updatedhttps://www.pharmaradar360.com/article/14b95a4514bb1516PharmaRadar360en2026-04-13T03:00:00.000Z[KOKUSAI]The report for the APEC CoE workshop: PMDA-ATC Pharacovigilance Seminar 2026 has been posted.https://www.pharmaradar360.com/article/4d6870b38d5595e3PharmaRadar360en2026-04-13T03:00:00.000Z[KOKUSAI]PMDA-ATC E-Learning Course contents have been released for FY2026https://www.pharmaradar360.com/article/54cabc71d5344dd7PharmaRadar360en2026-04-13T00:00:00.000Z2026å¹´4æ13æ¥ ãã¥ã¼ã¹ãªãªã¼ã¹ ã¢ã«ããã¤ãã¼ç é¢é£ãè¡æ¶²ä¸ã®p-Tau217ãæ¸¬å®ããç ç©¶ç¨è©¦è¬ãçºå£²https://www.pharmaradar360.com/article/b88ffa2d02a08aabPharmaRadar360en2026-04-13T00:00:00.000ZSysmex Launches an Assay Kit for Identifying p-Tau217 in the Blood, a Biomarker Related to Alzheimer's Diseasehttps://www.pharmaradar360.com/article/82c82f3e675d6931PharmaRadar360en2026-04-13T00:00:00.000ZSysmex to Serve as Special Sponsor of Kobe Marathon 2026 â Supporting the Event Toward a Healthy, Prosperous Society and Vibrant Local Communities âhttps://www.pharmaradar360.com/article/203a3efa16b1304cPharmaRadar360en2026-04-13T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/5df511eb97b201f2PharmaRadar360en2026-04-13T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/2c80a3ff78b576d8PharmaRadar360en2026-04-13T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/439b95cd7a2c5901PharmaRadar360en2026-04-13T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/68c96c3452096872PharmaRadar360en2026-04-13T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/bf2ae43ac3a8225fPharmaRadar360en2026-04-13T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/7e58ed1119f2b704PharmaRadar360en2026-04-13T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/0ce94e38bf999702PharmaRadar360en2026-04-13T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/e85ab22e547244adPharmaRadar360en2026-04-13T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/e418c83ae7f230f9PharmaRadar360en2026-04-13T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/c7f20c9aa9485624PharmaRadar360en2026-04-13T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/47c4b09686b67145PharmaRadar360en2026-04-13T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/1ce2024dfd0d2bd1PharmaRadar360en2026-04-13T00:00:00.000Z6203https://www.pharmaradar360.com/article/12cff47269c5dc28PharmaRadar360en2026-04-13T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/8d8c391caf92f7f3PharmaRadar360en2026-04-12T14:10:11.000ZGSK plans five Phase 3 studies for gynecological cancer ADC from Hansohhttps://www.pharmaradar360.com/article/d10b0fa4924d152fPharmaRadar360en2026-04-12T12:00:00.000ZGSK presents positive data for B7-H4-targeted ADC in gynaecological cancershttps://www.pharmaradar360.com/article/6539ba502e680f06PharmaRadar360en2026-04-12T11:15:00.000ZAbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026